References
- Macdougall IC , RossertJ , CasadevallNet al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia . N. Engl. J. Med.361 ( 19 ), 1848 – 1855 ( 2009 ).
- Bennett CL , LuminariS , NissensonARet al. Pure red-cell aplasia and epoetin therapy . N. Engl. J. Med.351 ( 14 ), 1403 – 8 ( 2004 ).
- McKoy JM , StonecashRE , CournoyerDet al. Epoetin-associated pure red cell aplasia: past, present, and future considerations . Transfusion48 ( 8 ), 1754 – 1762 ( 2008 ).
- Health Sciences Authority . Update on Eprex® and pure red cell aplasia (30 December 2002) . www.hsa.gov.sg/content/hsa/en/Health_Products_Regulation/Safety_Information_and_Product_Recalls/Product_Safety_Alerts/2002/epoetinalfa.html .
- Health Sciences Authority . Contraindication of subcutaneous administration of Eprex® (epoetin alfa) in Singapore in chronic kidney disease patients (31 December 2013) . www.hsa.gov.sg/content/hsa/en/Health_Products_Regulation/Safety_Information_and_Product_Recalls/Product_Safety_Alerts/2013/contraindication_of.html .
- Kaniwa N , SaitoY . Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury . J. Hum. Genet.58 ( 6 ), 317 – 326 ( 2013 ).
- Praditpornsilpa K , KupatawintuP , MongkonsritagoonWet al. The association of anti-r-HuEpo-associated pure red cell aplasia with HLA-DRB1*09–DQB1*0309 . Nephrol. Dial. Transplant.24 ( 5 ), 1545 – 1549 ( 2009 ).
- Casadevall N , CournoyerD , MarshJet al. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia . Eur. J. Haematol.73 ( 6 ), 389 – 396 ( 2004 ).
- Wong L-P , PohW-T , ChanS-Let al. Singapore Pharmacogenomics Portal: a web resource for evaluating human genetic variations of genes responsible for drug responses . Pharmacogenet. Genom.23 ( 6 ), 329 – 332 ( 2013 ).
- Pillai NE , OkadaY , SawW-Yet al. Predicting HLA alleles from high-resolution SNP data in three southeast Asian populations . Hum. Mol. Genet.23 ( 16 ), 4443 – 4451 ( 2014 ).
- Boven K , StrykerS , KnightJet al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes . Kidney Int.67 ( 6 ), 2346 – 2353 ( 2005 ).
- Macdougall IC , CasadevallN , LocatelliFet al. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS) . Nephrol. Dial. Transplant.30 ( 3 ), 451 – 460 ( 2015 ).
- Bennett CL , CournoyerD , CarsonKRet al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) project . Blood.106 ( 10 ), 3343 – 3347 ( 2005 ).
- Boven K , KnightJ , BaderF , RossertJ , EckardtK-U , CasadevallN . Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery . Nephrol. Dial. Transplant.20 ( Suppl. 3 ), iii33 – iii40 ( 2005 ).
- Chung W , HungS , ChenY . Human leukocyte antigens and drug hypersensitivity . Curr. Opin. Allergy Clin. Immunol.7 ( 4 ), 317 – 323 ( 2007 ).
- Fijal B , RicciD , VercammenEet al. Case–control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia . Pharmacogenomics.9 ( 2 ), 157 – 167 ( 2008 ).